Cancer prostate familial, Totul despre cancerul de prostata, simptome si tratament
This lack of preventive organisation kept the mortality rates, second or third in men in most countries, unchanged over the last decade and resulted in a prevalence figure of above 2 million in the European Union. Moreover in many cancer prostate familial it takes up to 20 years for initial subclinical microscopic tumours to reach the size of clinical detection; and after detection 10 to 15 years of disease may be possible before they reach the final lethal stage.
Is the Commission willing to take all necessary steps to obtain current and accurate data on incidence, its recent rise, early detection, treatment and prevalence in all Member States of the European Union? When will this information be available?
- Informatii generale si recomandari pentru efectuarea testului genetic Cancerul de prostata este cea mai frecventa forma de cancer care apare la barbati.
- Afla in acest articol totul despre cancerul de prostata, care sunt simptomele, tratamentul si rata de supravietuire.
- Cancer de prostata-mutatii ELAC2, RNASEL, BRCA2, SRD5A2 | Synevo
Will the Commission take into account in the Seventh Framework Cancer prostate familial the existing remarkable difference in mortality between southern and northern Europe, offering a unique opportunity to study cancer prostate familial and diet factors that promote or inhibit the growth of prostate cancer?
Is the Commission willing to speed up the analysis of the results of the only two randomised screening trials for prostate cancer, the pan European ERSPC and the Protect Study of the UK, respectively expected by and to secure a scientific base for policy decisions on prostate cancer population screening? Is the Commission willing and able to inform the population of the fact that maybe half of all newly detected prostate cancer on the basis of the Prostate Specific Antigen PSA test, without other indications cancer prostate familial disease, do not need treatment and may be best served by diagnostic follow-up rather than over-treatment?
How does the Commission intend to assist in the transition from the current PSA cancer prostate familial, with its limited accuracy for diagnosis, to a more accurate marker for diagnosis and prognosis?
How will the Commission support awareness of the fact that familial prostate and breast cancer in close relatives calls for early diagnostic screening from the age of 40? Last updated: 20 March